证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023010 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 国泰君安 孙超先 肖天莱 朱建华 王灿 参与单位名称及 元朔投资 梁艳仪 人员姓名 时间 2023-11-23（上午10:15-上午 11:30） 地点 广州市高新技术开发区科学城香山路19 号（公司总部） 上市公司接待人 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 员姓名 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：公司现在具有充足的现金流，是否考虑未来做一些并 ...

附件： 注：右四为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Performance and Pricing Strategy - The initial price of the company's COVID-19 products was over 100 yuan, which has decreased to over 3 yuan after several rounds of large-scale procurement [1] - The company has maintained good financial performance despite the declining product prices [1][2] - The reduction in production costs is attributed to large-scale production and technological improvements, allowing for better cost control [2] Group 2: Market Share and Product Development - The company has achieved a market share of up to 60% for some products, maintaining a high market presence since its listing in 2004 [2] - The product range includes respiratory pathogens, influenza pathogens, gastrointestinal and foodborne pathogens, reproductive health, personalized tumor testing, and genetic testing [2] Group 3: Financial Outlook and Strategic Plans - The decline in profit during the third quarter was primarily due to product price adjustments and operational restructuring [2] - The company is cautiously optimistic about future investments and acquisitions, focusing on market trends and technological advancements [2] - There is a growing trend in the molecular market, with potential for molecular products to gradually replace immunological or biochemical products [2][3]

附件： 注：左三为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Overview and Financials - The company raised 160 million yuan during its IPO and has not pursued further financing or corporate bond issuance since then [2] - The company relies on self-sustained growth through scale production and continuous product innovation [2] Group 2: Market Adaptation and Policy Response - The introduction of the price negotiation and procurement policy is beneficial for innovative large-scale IVD companies, testing their adaptability to new market rules [1] - Product pricing will be influenced by national policies and market competition, with the company closely monitoring these factors [2] Group 3: Product Development and Export Strategy - The company has exported PCR products to over 140 countries, indicating a strong international presence and capacity [2] - The company is focusing on expanding its product line in the field of chemiluminescence and has entered the full IVD domain, emphasizing diagnostic technology and products [3] Group 4: Future Directions - The company aims to strengthen its position in PCR and molecular diagnostics while actively developing immunology, biochemistry, and analytical instruments [3] - The company is committed to becoming a "IVD World Factory" with a complete product chain and high cost-performance products [2]

| --- | --- | --- | |-----------------------------------------------------|------------------|-------------------| | 收到的税费返还 | 86,163,145.18 | 7,922,143.12 | | 收到其他与经营活动有关的现金 | 827,296,571.15 | 634,726,897.69 | | 经营活动现金流入小计 | 3,507,663,447.72 | 8,150,522,628.03 | | 购买商品、接受劳务支付的现金 | 982,131,891.61 | 2,240,773,043.75 | | 客户贷款及垫款净增加额 | 0.00 | 0.00 | | 存放中央银行和同业款项净增加额 | 0.00 | 0.00 | | 支付原保险合同赔付款项的现金 | 0.00 | 0.00 | | 拆出资金净增加额 | 0.00 | 0.00 | | 支付利息、手续费及佣金的现金 | 0.00 | 0.00 | | 支付保单红利的现金 | 0.00 | 0.00 | | 支付给职工及 ...

附件: 热泵以欢迎机构投资者 疫情态安装团购物 E L R R R R R R 注:左七为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码:002030 证券简称:达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号:2023006 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 √现场参观 □其他() 中金财富 叶智玲 黄雯 东兴证券 李绍如 广澜资本 魏仕驰 黄镇雅 大中资产 蔡志辉 麻王集团 陈均健 冯健饶 参与单位名称及 博源基金 程小菁 人员姓名 前海鸿富投资 吴辉玲 东莞私募基金协会 李婷婷 新加坡莱富士金融 陈小宇 黄钦鉴 东莞松山湖招商引智办 林锡聪 时间 2023-09-13(下午 15:00-下午 17:30) 地点 广州市高新技术开发区科学城香山路 19 号(公司总部) 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况(以调研机构提问,公司高管回答 投资者关系活动 的方式展开) 主要内容介绍 问题一:公司在年报中有提及,"加快全球布局及海外市场业 务拓展的步伐",现在公司在国际市场上的人力资源和战略配 置进展如何? 答:公司近年来持续以国际化视角积极探索和布局"走出去" 的模式和路径。为适应各国的政策 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥536,218,449.35, a decrease of 91.97% compared to the same period last year[51]. - The net profit attributable to shareholders of the listed company was ¥402,755,388.71, down 88.80% year-on-year[51]. - The net profit after deducting non-recurring gains and losses was ¥102,897,120.82, a decline of 97.03% compared to the previous year[51]. - The net cash flow from operating activities was -¥38,382,493.67, a decrease of 102.25% compared to the same period last year[51]. - Basic earnings per share were ¥0.29, down 88.67% from ¥2.56 in the same period last year[51]. - Total assets at the end of the reporting period were ¥11,708,971,705.38, a decrease of 20.66% from the end of the previous year[51]. - The net assets attributable to shareholders of the listed company were ¥9,187,500,489.81, down 18.70% from the previous year[51]. - The weighted average return on net assets was 3.50%, a decrease of 36.95% compared to 40.45% in the same period last year[51]. - The company reported a total non-operating income of 299,858,267.89 CNY, with a significant portion attributed to non-recurring gains[73]. - The fair value changes from trading financial assets and derivatives generated a profit of 176,366,249.20 CNY, classified as regular operating income due to the nature of the business[73]. - The company reported a total profit for the period of CNY 487,312,008.57, down 88.76% year-on-year[114]. - The investment income decreased by 89.57% to ¥20,089,978.44, primarily due to the disposal of equity in joint ventures in the same period last year[172]. - The gross margin for the bioproducts sector was 52.32%, down by 23.50% year-on-year[175]. Environmental and Regulatory Compliance - The company has been classified as a key environmental risk control unit due to hazardous waste generation exceeding 100 tons per year, leading to stricter waste management protocols[9]. - The company has not experienced any sudden environmental incidents during the reporting period, and conducted emergency drills for hazardous chemicals in June 2023[10]. - The company has received multiple environmental impact assessment approvals for various projects, indicating ongoing expansion and compliance with regulatory requirements[30]. - The company’s major pollutants include noise, waste gas, wastewater, and solid waste, with noise levels recorded at 58.7 dB(A), below the standard limit of 60 dB(A)[32]. Strategic Initiatives and Market Position - The company is adapting to new market operational rules due to ongoing reforms in the pharmaceutical and healthcare sectors, particularly in the in vitro diagnostics industry[5]. - The company is exploring market expansion opportunities, particularly in the healthcare diagnostics sector, to leverage growth potential[75]. - The company is committed to enhancing its operational efficiency and profitability through strategic investments and product innovation[75]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its capabilities and market reach[77]. - The company is focused on expanding its market presence through the introduction of new products and technologies, particularly in the field of infectious disease testing[77]. - The company has established a multi-level incentive mechanism to improve human resource management and enhance operational efficiency[145]. - The company has implemented a comprehensive performance and incentive management system to enhance employee morale and efficiency[119]. Research and Development - The company is investing in research and development to enhance its product offerings, particularly in the areas of genetic testing and infectious disease diagnostics[77]. - The company continues to invest in R&D, enhancing its core competitiveness through an efficient and open research platform[116]. - The company is focusing on research innovation and the application of new technologies and products to drive revenue and profit growth in the biopharmaceutical sector[4]. - The company emphasizes the importance of continuous technological innovation and new product launches in the IVD industry to maintain competitive advantage[192]. Product Portfolio and Market Trends - The company has a diverse product line including various nucleic acid testing kits for viruses such as COVID-19, hepatitis B, and influenza, indicating a strong focus on healthcare products[75]. - The company has launched a series of diagnostic products covering tumor markers, hepatitis, hormones, prenatal screening, and more, with multiple product approvals in 2022[1]. - The company has developed multiple advanced diagnostic technology platforms, including nucleic acid and immunological diagnostic technology[150]. - The company has over 500 registered medical device certificates and more than 100 invention patents, indicating a strong product reserve[151]. - The global IVD market is experiencing rapid growth, becoming a market worth hundreds of billions, with expectations for continued expansion due to new technologies and products[83]. - The domestic IVD product industry is rapidly developing, with accelerated innovation across various technology platforms and an increasing number of application products[85]. - The company has established itself as a leader in the molecular diagnostics industry, with prominent brands such as "Da An Gene" and "Da Rui Bio" leading the market[88]. Financial Management and Corporate Governance - The company has not undergone any bankruptcy reorganization during the reporting period[35]. - The company has not reported any changes in its board of directors or senior management during the reporting period[28]. - The company plans to not distribute cash dividends or issue bonus shares for the reporting period[19]. - The company has not reported any significant losses from entrusted loans or investment properties, indicating stable financial management[73]. - The company has not utilized any raised funds during the reporting period[187]. - There were no significant asset sales during the reporting period[188]. - The company does not engage in derivative investments during the reporting period[186].

证券代码：002030 证券简称：达安基因 编号：2023005 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 中信证券 张秋尘 贾皓阳 参与单位名称及 毅恒资本 郭远山 郑达鑫 人员姓名 时间 2023-07-21（下午 15:30-下午 17:00） 地点 广州市高新技术开发区科学城香山路 19 号（公司总部） 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：站着企业长期发展的视角来看，公司未来五年的规划 是什么？ 答：公司主要发展方向就是从分子诊断领域走向IVD全诊断领 投资者关系活动 域。未来公司将全面落实进入IVD全领域的发展策略，聚焦于 主要内容介绍 诊断技术和产品的临床、公共卫生、检验检疫、生命健康相关 领域等全场景应用，继续做大做强PCR及分子诊断技术、产品 和市场领域，积极发展免疫、生化、分析仪器等全诊断技术平 台、产品和市场领域。 问题二：达安所具备的和其他企业的不同的独特点是什么？是 广州达安基因股份有 ...